Clinical

Patrick Campbell is the assistant managing editor of Endocrinology Network, as well as its sister publication Practical Cardiology. Prior to joining these brands, he led coverage of cardiology and diabetes with HCPLive. Before joining parent company MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a freelance multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record.  Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Articles

The ESTIMABL2 trial indicates a follow-up strategy not involving use of radioiodine was noninferior to ablation strategies with radioiodine for the occurrence of functional, structural, and biologic events up to 3 years after thyroidectomy. 

No Radioiodine Proven Noninferior to Postoperative Radioiodine After Thyroidectomy in Low-Risk Thyroid Cancer

A new analysis from UNSW Sydney details the prevalence of thyroid cancers in the next decade attributable to current levels of overweight and obesity among the population in Australia. 

Obesity, Overweight Responsible for 1-in-5 Future Thyroid Cancers in Australia

A systematic review and meta-analysis presented at AACE 2021 details the risk of cardiovascular disease in patients with thyroid cancer who have undergone thyroidectomy. 

AACE 2021 Analysis Details Risk of Cardiovascular Disease, AFib, and CV Death in Thyroid Cancer Patients

A survey of more than 600 physicians found many endorsed the use of thyroid ultrasonography for clinically unsupported reasons. 

Nearly 1-in-3 of Physicians Could Be Overusing Thyroid Ultrasonography

New research is defining how primary care providers view their role in long-term survivorship care of patients with thyroid cancer.

Primary Care's Perception of Role in Thyroid Cancer Survivorship Care 

The American Thyroid Association guidelines recommend repeat fine-needle aspiration, molecular testing or diagnostic surgical resection if thyroid nodule size increases significantly, but a new study shows there is little evidence that significant tumor growth is a predictor of malignancy, especially in architectural atypia of undetermined significance (AUS-A) cases.

Tumor Growth Rate Doesn’t Predict Malignancy in AUS-A Thyroid Nodules

Slideshows

Our May list includes a new treatment for osteoporosis, predictors of thyroid cancer recurrence, and fast-acting vs conventional insulin for T1DM.

 Interesting Endo: Osteoporosis & Thyroid Cancer

Our November list includes an injectable male contraceptive, resveratrol treatment for PCOS, and novel gene associated with Addison disease.

Interesting Endo: Reproductive and Adrenal Health

Is thyroid cancer the exception to the rule that alcohol consumption is linked to an increased risk of developing cancer?

Thyroid Cancer